-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV
CAS No. | Product Name | Inquiry |
---|---|---|
2761367-25-1 |
Antiviral agent 25 |
|
2761911-40-2 |
SARS-CoV-2-IN-16SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand. |
|
2761911-44-6 |
SARS-CoV-2-IN-17SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand. |
|
2763495-65-2 |
PB49673382 |
|
2763596-72-9 |
Olgotrelvir Sodium |
|
2765088-93-3 |
SARS-CoV-2-3CLpro-IN-2SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases. |
|
2765433-05-2 |
MAT-POS-e194df51-1 |
|
2766185-81-1 |
SP inhibitor 1 |
|
2768834-39-3 |
SARS-CoV-MPro-IN-2SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in drug discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19. |
|
2768834-48-4 |
SARS-CoV-2 Mpro-IN-6 |
|
2773516-53-1 |
Zevotrelvir |
|
2779498-79-0 |
Mindeudesivir hydrobromide |
|
278603-08-0 |
NH125NH125 is a potent and selective eEF-2 kinase inhibitor with an IC50 of 60 nM, and also a potent histidine kinase inhibitor. It shows >125-fold selectivity over PKC, PKA, and CaMKII. |
|
2809363-81-1 |
HCoV-OC43-IN-1 |
|
2816165-02-1 |
SARS-CoV-2 nsp14-IN-1 |
|
2816165-16-7 |
SARS-CoV-2 nsp14-IN-2 |
|
2817810-96-9 |
SARS-CoV-2-IN-95 |
|
2834087-69-1 |
HIV-1 inhibitor-50 |
|
2835511-03-8 |
GRL-1720 |
|
2863657-16-1 |
RdRP-IN-2RdRP-IN-2 is a small molecule inhibitor designed to target RNA-dependent RNA polymerase (RdRP), an enzyme essential for the replication of RNA viruses. RdRP-IN-2 inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM. By inhibiting RdRP, RdRP-IN-2 aims to disrupt the viral replication process, potentially reducing the viral load and mitigating the severity of infections caused by RNA viruses. This type of inhibitor is valuable in the development of antiviral therapies, especially for diseases caused by viruses with RNA genomes, such as certain coronaviruses, flaviviruses, and other RNA viruses. |
※ Please kindly note that our services are for research use only.